Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
Invest New Drugs
; 4(3): 275-8, 1986.
Article
em En
| MEDLINE
| ID: mdl-3469171
ABSTRACT
Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Broncogênico
/
Daunorrubicina
/
Neoplasias Pulmonares
/
Antibióticos Antineoplásicos
Tipo de estudo:
Guideline
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
1986
Tipo de documento:
Article